News | Contrast Media | February 04, 2016

Akrotome Imaging Receives $1.7M NIH Research Grant for Sprayable Cancer Imaging Agent

Imaging probes can be sprayed on cancerous tissue rather than delivered via IV, speeding FDA approval time and immediately alerting surgeons if all cancer cells have been removed

February 4, 2016 — Akrotome Imaging Inc. received a major award from the National Institutes of Health (NIH) in November to complete development and commercialization of its new imaging platform.

The $1.7M grant will fund the development of an imaging instrument and a fluorescent molecular probe that “lights up” many kinds of previously invisible cancer cells, making it easier for surgeons to determine if all cancer cells have been removed or if additional surgeries are required.

Instead of requiring patients to receive large doses of probe via IV hours before the procedure, Akrotome developed something that could be easily sprayed on the tumor area to reveal traces of remaining cancer cells. Results are available in minutes and the patient does not need to be injected with probe.

While the probes can also be administered via IV, the external and topical applications of the probes mean they have fewer U.S. Food and Drug Administration (FDA) regulatory hurdles than competing probes and can reach the market faster and at a much lower cost.

Akrotome has a portfolio of probes that target cathepsins, cancer-associated enzymes that are expressed by 85 percent of solid tumors. Trials conducted by the company indicate the probe can highlight cancer cells with better than 95 percent accuracy. The probes and technologies were developed in the laboratories of Matthew Bogyo, Ph.D., at Stanford University and James Basilion, Ph.D., at Case Western Reserve University, with imaging capabilities provided by Indec Systems Inc.

Akrotome is currently moving its probes forward for use in skin and breast cancers. Future targets include colon, ovarian and lung tumors.

Research is supported by the National Cancer Institute of the National Institutes of Health under Award Number 2R44CA180296-02.

Related Content

Avoiding contrast dyes for imaging tests not necessary if concerned about iodine allergy, peer-reviewed study concludes #MRI

Getty Images

News | Contrast Media Injectors | September 16, 2021
September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthc
PET, PET imaging, PET-CT, FDG PET, PET cancer assessment, pet scanner, nuclear imaging, molecular imaging

A PET-CT head and neck cancer scan showing various image reconstructions. The top left image is the separate CT scan showing the anatomy. The top right scan shows the fused PET and CT scans with false color added to help interpret the image. The bottom left scan is an initial FDG PET image showing tracer hot spots in the neck and a lymph node in the right jaw due to cancer. The right bottom image is a delayed enhancement scan showing tracer uptake over time, with normal hot spots in the bladder, kidneys, testicles and brain, which normally have higher metabolic activity. The low-grade gray shading of the anatomy is due to the normal cellular metabolism uptake of the FDG throughout the body. 

News | PET-CT | August 04, 2021
August 4, 2021 — PET/CT systems are exp
According to ARRS’ American Journal of Roentgenology (AJR), the resources required to warm iohexol 350 to body temperature before injection for computed tomography (CT) may not be warranted, given the lack of observed practical benefit.

Values represent number of patients, with percentage in parentheses and 95% CI in brackets (not reported for levels of severity of allergic/allergic-like reactions). 95% CIs were calculated using the Clopper-Pearson exact formula. For events with zero frequency, one-sided 97.5% CIs are provided.

News | Contrast Media | July 30, 2021
IQ-AI subsidiary Imaging Biometrics (IB) was awarded a U.S. patent for its artificial intelligence (AI) software technology that eliminates the need for gadolinium-based contrast agents (GBCAs) in medical imaging exams.
News | Contrast Media | June 30, 2021
June 30, 2021 – IQ-AI subsid
The contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence and prevalence of chronic diseases and demand for diagnostic and interventional radiology procedures, increase in aging population, expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement

image courtesy of Guerbet

News | Contrast Media | May 03, 2021
Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or
Gadopiclenol is a high-relaxivity macrocyclic contrast agent used for magnetic resonance imaging (MRI)
News | Contrast Media | March 24, 2021
March 24, 2021 — Guerbet announced positive results from two...
(a) High-resolution 3D MRI brain vascular map using SAIO. Various blood vessels in the rat brain can be visualized. In addition to clinically important brain vessels including anterior cerebral artery, middle cerebral artery, posterior cerebral artery, fine vessel structures as thin as ~ 100 microns in diameter can be clearly visualized. (b) 3D MRI brain vascular map using Dotarem (gadolinium-based contrast agent). Resolution is low and microvessels are not visible. (c) For 3D reconstruction, multiple slice

(a) High-resolution 3D MRI brain vascular map using SAIO. Various blood vessels in the rat brain can be visualized. In addition to clinically important brain vessels including anterior cerebral artery, middle cerebral artery, posterior cerebral artery, fine vessel structures as thin as ~ 100 microns in diameter can be clearly visualized. (b) 3D MRI brain vascular map using Dotarem (gadolinium-based contrast agent). Resolution is low and microvessels are not visible. (c) For 3D reconstruction, multiple slices of MRI images of the rat heart were obtained after injection of SAIO. Rat coronary arteries (180 microns) which are 10 times thinner than human coronary arteries were successfully visualized. Coronary arteries supply blood to the heart muscle and the blockage or narrowing of such arteries causes myocardial infarction or angina, but visualizing these arteries was impossible due to the limited resolution of current MRI contrast agents. Image courtesy of Institute for Basic Science

News | Contrast Media | March 12, 2021
March 12, 2021 — Heart attack and stroke are the first and second leading causes of death in developed countries, res
Guerbet announced the launch of OptiProtect 3S, a new range of technical services for its injection solutions. OptiProtect 3S is designed to support imaging centers in the daily use and protection of their injection solutions.
News | Contrast Media Injectors | February 25, 2021
February 25, 2021 — Guerbet announced the launch of ...